Wuhan Hiteck Biological Pharma Co Ltd (300683) — Cash Flow-to-Debt Ratio
Wuhan Hiteck Biological Pharma Co Ltd (300683) has a Cash Flow-to-Debt Ratio of -0.04x as of September 2025, meaning its operating cash flow of CN¥-17.49 Million could theoretically repay 0% of its total liabilities (CN¥393.09 Million) in one year. Check how aggressively does Wuhan Hiteck Biological Pharma Co Ltd reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Wuhan Hiteck Biological Pharma Co Ltd Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Wuhan Hiteck Biological Pharma Co Ltd across 12 annual periods. Also explore total assets of Wuhan Hiteck Biological Pharma Co Ltd for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Wuhan Hiteck Biological Pharma Co Ltd (2013–2024)
Year-by-year debt coverage analysis for Wuhan Hiteck Biological Pharma Co Ltd. For market capitalisation and broader financial context, see Wuhan Hiteck Biological Pharma Co Ltd stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.04x | CN¥22.69 Million | CN¥525.05 Million | ▲ +286.8% |
| 2023 | 0.01x | CN¥5.31 Million | CN¥475.73 Million | ▼ -92.2% |
| 2022 | 0.14x | CN¥53.03 Million | CN¥371.20 Million | ▲ +318.9% |
| 2021 | 0.03x | CN¥12.09 Million | CN¥354.46 Million | ▲ +179.9% |
| 2020 | -0.04x | CN¥-19.70 Million | CN¥461.62 Million | ▼ -127.7% |
| 2019 | 0.15x | CN¥63.03 Million | CN¥409.03 Million | ▼ -6.4% |
| 2018 | 0.16x | CN¥73.42 Million | CN¥445.77 Million | ▼ -47.3% |
| 2017 | 0.31x | CN¥83.08 Million | CN¥265.62 Million | ▼ -27.0% |
| 2016 | 0.43x | CN¥143.86 Million | CN¥335.87 Million | ▼ -26.1% |
| 2015 | 0.58x | CN¥159.89 Million | CN¥275.74 Million | ▲ +13.4% |
| 2014 | 0.51x | CN¥135.40 Million | CN¥264.78 Million | ▲ +24.1% |
| 2013 | 0.41x | CN¥76.82 Million | CN¥186.42 Million | — |